To determine whether patients with muscle-invasive bladder cancer (MIBC) and ureteral obstruction can safely receive neoadjuvant cisplatin-based chemotherapy (NAC). Also, to determine whether such patients require relief of obstruction with a ureteral stent or percutaneous nephrostomy (PCN) prior to beginning NAC.